New pill aims to fight daytime sleepiness in narcolepsy

NCT ID NCT07502443

Recruiting now Symptom relief Sponsor: Alkermes, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 01, 2026 · Last updated May 22, 2026 · Updated 7 times

Summary

This study tests a new medication, ALKS 2680, to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the drug or a placebo. The main goal is to measure how well they can stay awake during the day after 12 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alkermes Investigational Site
RECRUITING

Brandon, Florida, 33511, United States
Alkermes Investigational Site
RECRUITING

Macon, Georgia, 31210, United States
Alkermes Investigational Site
NOT_YET_RECRUITING

Lansing, Michigan, 48911, United States
Alkermes Investigational Site
RECRUITING

Cincinnati, Ohio, 45245, United States
Alkermes Investigational Site
RECRUITING

Wyomissing, Pennsylvania, 19610, United States
Alkermes Investigational Site
RECRUITING

Columbia, South Carolina, 29201, United States
Alkermes Investigational Site
RECRUITING

Austin, Texas, 78731, United States
Alkermes Investigational Site
RECRUITING

Sugar Land, Texas, 77478, United States

Conditions

Explore the condition pages connected to this study.

NARCOLEPSY TYPE 2